GLP1R and type 2 diabetes mellitus: On the other hand, exenatide, a GLP-1 receptor agonist, showed improved pituitary and hypothalamic sensitivity to thyroid hormone action in patients with T2DM by reducing serum TSH levels in 12 months [40].